Fesoterodine in patients with overactive bladder syndrome: Can the severity of baseline urgency urinary incontinence predict dosing requirement?

BJU International

Volumn 106, Issue 6, 2010, Pages 816-821

  Cardozo, Linda ^a   Khullar, Vik ^b   Wang, Joseph T ^c   Guan, Zhonghong ^c   Sand, Peter K ^d  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c PFIZER INC   (United States)

^d NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

fesoterodine; frequency; overactive bladder syndrome; urgency urinary incontinence

Indexed keywords

FESOTERODINE; PLACEBO; TOLTERODINE; BENZHYDRYL DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BACKACHE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DRY THROAT; DYSPEPSIA; DYSURIA; FEMALE; HEADACHE; HUMAN; INFLUENZA; KERATOCONJUNCTIVITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OVERACTIVE BLADDER; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URGENCY URINARY INCONTINENCE; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; XEROSTOMIA; COMPLICATION; DOSE RESPONSE; EPIDEMIOLOGY; MIDDLE AGED; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, URGE;

AGED; BENZHYDRYL COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, URGE;

EID: 77956196306     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09202.x     Document Type: Article

References (30)

1. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008 54 : 543 562
2. Cardozo L, Lisec M, Millard R et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004 172 : 1919 1924
3. Hill S, Khullar V, Wyndaele JJ, Lheritier K. Dose-response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct 2006 17 : 239 247
4. Rogers R, Bachmann G, Jumadilova Z et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int Urogynecol J Pelvic Floor Dysfunct 2008 19 : 1551 1557
5. MacDiarmid SA. Overactive bladder: improving the efficacy of anticholinergics by dose escalation. Curr Urol Rep 2003 4 : 446 451
6. Corcos J, Casey R, Patrick A et al. A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. BJU Int 2006 97 : 520 527
7. Chapple CR, Rechberger T, Al-Shukri S et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004 93 : 303 310
8. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004 45 : 420 429
9. Steers W, Corcos J, Foote J, Kralidis G. An investigation of dose titration with darifenacin, an M-selective receptor antagonist. BJU Int 2005 95 : 580 586
10. Khullar V, Rovner ES, Dmochowski R, Nitti V, Wang J, Guan Z. Fesoterodine dose-response in subjects with overactive bladder syndrome. Urology 2008 71 : 839 843
11. Tubaro A, De Nunzio C. Comparison of peripherally active substance for treatment of detrusor overactivity: what is new; what is in the pipeline. EAU Update 2004 2 : 161 169
12. Cole P. Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update. Drugs Future 2004 29 : 715 720
13. Nilvebrant L. The mechanism of action of tolterodine. Rev Contemp Pharmacother 2000 11 : 13 27
14. Nilvebrant L. Clinical experiences with tolterodine. Life Sci 2001 68 : 2549 2556
15. Postlind H, Danielson A, Lindgren A, Andersson SH. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 1998 26 : 289 293
16. Chapple C, Van Kerrebroeck P, Tubaro A et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007 52 : 1204 1212
17. Nitti V, Dmochowski R, Sand P et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007 178 : 2488 2494
18. Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006 49 : 1079 1086
19. Sachse R, Cawello W, Haag MC, Horstmann R. Dose-proportional pharmacokinetics of the new antimuscarinic fesoterodine. Arch Pharmacol 2003 367 : 446 [abstract]
20. Mukerji G, Yiangou Y, Grogono J et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 2006 176 : 367 373
21. Cawello W, Auer S, Hammes W, Sachse R, Horstmann R. Multiple dose pharmacokinetics of fesoterodine in human subjects. Naunyn Schmiedebergs Arch Pharmacol 2002 365 : 428 [abstract]
22. Hesch K. Agents for treatment of overactive bladder: a therapeutic class review. Proc (Bayl Univ Med Cent) 2007 20 : 307 314
23. Gomez A, Martos F, Bellido I et al. Muscarinic receptor subtypes in human and rat colon smooth muscle. Biochem Pharmacol 1992 43 : 2413 2419
24. Irwin DE, Milsom I, Kopp Z, Abrams P. Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol 2008 53 : 1029 1037
25. Sand PK, Steers WD, Dmochowski R, Andoh M, Forero-Schwanhaeuser S. Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin. Int Urogynecol J Pelvic Floor Dysfunct 2009 20 : 667 675
26. Coyne KS, Zhou Z, Thompson C, Versi E. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int 2003 92 : 731 735
27. Elinoff V, Bavendam T, Glasser DB, Carlsson M, Eyland N, Roberts R. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract 2006 60 : 745 751
28. Coyne KS, Zyczynski T, Margolis MK, Elinoff V, Roberts RG. Validation of an overactive bladder awareness tool for use in primary care settings. Adv Ther 2005 22 : 381 394
29. Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zycyzynski T, Coyne KS. Test-retest reliability of four questionnaires for patients with overactive bladder: the Overactive Bladder Questionnaire (OAB-q), Patient Perception of Bladder Condition (PPBC), Urgency Questionnaire (UQ), and the Primary OAB Symptom Questionnaire (POSQ). Neurourol Urodyn 2005 24 : 215 225
30. Brubaker L, Woodson K, Beach J et al. Self-Assessment Goal Achievement Questionnaire: baseline results of a pilot study in U.S. subjects with overactive bladder. In Society of Urologic Nurses and Associates 40th Annual Conference, 2009 October 2-5, 2009. Chicago, Illinois